Company news
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) news
Monte Rosa Therapeutics, Inc. news releases on 6ix. Latest, Oct 2, 2026: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 1, 2026
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
September 30, 2026
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
September 30, 2026
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
September 29, 2026
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
September 8, 2026
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
August 24, 2026
Monte Rosa Therapeutics: Q2 Earnings Snapshot
August 6, 2026
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
August 6, 2026
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
May 7, 2026
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 5, 2026
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
April 20, 2026
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
March 16, 2026
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
March 15, 2026
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
February 23, 2026
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
January 7, 2026
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
January 7, 2026
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
January 7, 2026
Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results
January 6, 2026
Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations
December 16, 2025
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results
December 15, 2025
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
November 8, 2025
Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates
November 6, 2025
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
November 3, 2025
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
October 24, 2025
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
September 15, 2025
Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates
August 7, 2025
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
July 21, 2025
Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines
July 3, 2025
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
June 10, 2025
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 28, 2025
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
May 8, 2025
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
April 28, 2025
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
March 20, 2025
Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025
March 11, 2025
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
January 9, 2025
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
December 12, 2024
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
December 10, 2024
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors
December 4, 2024
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
November 6, 2024
Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders
October 27, 2024
Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors
October 22, 2024
Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study
August 18, 2024
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 7, 2024
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
June 26, 2024
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 13, 2024
Monte Rosa Therapeutics Announces Leadership Team Promotions
May 29, 2024
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
May 20, 2024
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
May 15, 2024